PCSK9通过结合血小板CD36增强血小板活化、血栓形成及心肌梗死扩展
该研究探讨PCSK9对血小板活化和血栓形成的直接作用及机制。体外实验显示PCSK9直接增强激动剂诱导的血小板聚集、致密颗粒ATP释放、整合素αIIbβ3活化、α颗粒P-选择素释放、铺展和血块回缩;体内FeCl3损伤小鼠肠系膜小动脉血栓模型证实PCSK9增强血栓形成,而PCSK9抑制剂依洛尤单抗改善其增强效应。机制上PCSK9结合血小板CD36激活Src激酶及下游信号通路,CD36敲除小鼠证实该效应依赖CD36;阿司匹林可消除PCSK9的增强效应;心肌梗死模型显示PCSK9激活血小板CD36加重微血管阻塞并促进梗死扩展。
要点
- PCSK9直接增强血小板活化和体内血栓形成,该效应依赖血小板CD36。
- 阿司匹林和PCSK9抑制剂均可消除PCSK9对血小板活化和血栓形成的增强效应。
- PCSK9激活血小板CD36加重心肌梗死后微血管阻塞并促进梗死扩展。
核心结论
- 血浆PCSK9通过结合血小板CD36激活下游信号通路,直接增强血小板活化和体内血栓形成,并促进心肌梗死后梗死扩展。
- PCSK9抑制剂或阿司匹林可消除PCSK9的增强效应,支持在高血浆PCSK9水平患者中联合使用阿司匹林和PCSK9抑制剂预防血栓并发症。
研究设计与样本
- 体外检测PCSK9对激动剂诱导的血小板聚集、致密颗粒ATP释放、整合素αIIbβ3活化、α颗粒释放、铺展和血块回缩的直接效应。
- 体内采用FeCl3损伤小鼠肠系膜小动脉血栓模型分析血栓形成。
- 机制研究使用CD36敲除小鼠,并采用心肌梗死模型探索PCSK9对微血管阻塞和梗死扩展的影响。
主要发现
- PCSK9直接增强激动剂诱导的血小板聚集、致密颗粒ATP释放、整合素αIIbβ3活化、α颗粒P-选择素释放、铺展和血块回缩。
- PCSK9增强FeCl3损伤小鼠肠系膜小动脉体内血栓形成,PCSK9抑制剂依洛尤单抗改善其增强效应。
- PCSK9结合血小板CD36激活Src激酶和MAPK-细胞外信号调节激酶5及c-Jun N末端激酶,增加活性氧生成,并激活p38MAPK/胞质磷脂酶A2/环氧合酶-1/血栓素A2信号通路。
- CD36敲除小鼠证实PCSK9对血小板活化的增强效应依赖CD36。
- 阿司匹林一致地消除PCSK9对血小板活化和体内血栓形成的增强效应;PCSK9激活血小板CD36加重微血管阻塞并促进心肌梗死后梗死扩展。
临床怎么用
- 在高血浆PCSK9水平患者中,除PCSK9抑制剂外可考虑使用阿司匹林以预防血栓并发症。
- PCSK9抑制剂可能通过抑制PCSK9对血小板的直接增强效应而减少血栓风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin 9), mainly secreted by the liver and released into the blood, elevates plasma low-density lipoprotein cholesterol by degrading low-density lipoprotein receptor. Pleiotropic effects of PCSK9 beyond lipid metabolism have been shown. However, the direct effects of PCSK9 on platelet activation and thrombosis, and the underlying mechanisms, as well, still remain unclear. METHODS: We detected the direct effects of PCSK9 on agonist-induced platelet aggregation, dense granule ATP release, integrin αIIbβ3 activation, α-granule release, spreading, and clot retraction. These studies were complemented by in vivo analysis of FeCl3-injured mouse mesenteric arteriole thrombosis. We also investigated the underlying mechanisms. Using the myocardial infarction (MI) model, we explored the effects of PCSK9 on microvascular obstruction and infarct expansion post-MI. RESULTS: PCSK9 directly enhances agonist-induced platelet aggregation, dense granule ATP release, integrin αIIbβ3 activation, P-selectin release from α-granules, spreading, and clot retraction. In line, PCSK9 enhances in vivo thrombosis in a FeCl3-injured mesenteric arteriole thrombosis mouse model, whereas PCSK9 inhibitor evolocumab ameliorates its enhancing effects. Mechanism studies revealed that PCSK9 binds to platelet CD36 and thus activates Src kinase and MAPK (mitogen-activated protein kinase)-extracellular signal-regulated kinase 5 and c-Jun N-terminal kinase, increases the generation of reactive oxygen species, and activates the p38MAPK/cytosolic phospholipase A2/cyclooxygenase-1/thromboxane A2 signaling pathways downstream of CD36 to enhance platelet activation, as well. Using CD36 knockout mice, we showed that the enhancing effects of PCSK9 on platelet activation are CD36 dependent. It is important to note that aspirin consistently abolishes the enhancing effects of PCSK9 on platelet activation and in vivo thrombosis. Last, we showed that PCSK9 activating platelet CD36 aggravates microvascular obstruction and promotes MI expansion post-MI. CONCLUSIONS: PCSK9 in plasma directly enhances platelet activation and in vivo thrombosis, and MI expansion post-MI, as well, by binding to platelet CD36 and thus activating the downstream signaling pathways. PCSK9 inhibitors or aspirin abolish the enhancing effects of PCSK9, supporting the use of aspirin in patients with high plasma PCSK9 levels in addition to PCSK9 inhibitors to prevent thrombotic complications.
引用
- Qi Z, Hu L, Zhang J, et al. PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36. Circulation. 2020. PMID: 32988222. doi:10.1161/CIRCULATIONAHA.120.046290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。